Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Confirmation of a metastasis-specific microRNA signature in primary colon cancer.

Coebergh van den Braak RRJ, Sieuwerts AM, Lalmahomed ZS, Smid M, Wilting SM, Bril SI, Xiang S, van der Vlugt-Daane M, de Weerd V, van Galen A, Biermann K, van Krieken JHJM, Kloosterman WP, Foekens JA; MATCH study group*, Martens JWM, IJzermans JNM.

Sci Rep. 2018 Mar 27;8(1):5242. doi: 10.1038/s41598-018-22532-1.

2.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
3.

Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.

Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR, Goel A.

J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju492. doi: 10.1093/jnci/dju492. Print 2015 Mar.

4.

Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer.

Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP.

Oncotarget. 2017 Sep 23;8(50):87837-87847. doi: 10.18632/oncotarget.21237. eCollection 2017 Oct 20.

5.

MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.

Marino AL, Evangelista AF, Vieira RA, Macedo T, Kerr LM, Abrahão-Machado LF, Longatto-Filho A, Silveira HC, Marques MM.

BMC Cancer. 2014 Oct 2;14:739. doi: 10.1186/1471-2407-14-739.

6.

Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.

Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra C, Kopetz S, Wang X, Goel A.

Clin Cancer Res. 2018 Aug 15;24(16):3867-3877. doi: 10.1158/1078-0432.CCR-17-3236. Epub 2018 Mar 7.

7.

miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.

Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, Shen L, Yu J.

Oncogene. 2015 Jul 30;34(31):4142-52. doi: 10.1038/onc.2014.348. Epub 2014 Nov 3.

PMID:
25362853
8.

Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.

Giráldez MD, Lozano JJ, Cuatrecasas M, Alonso-Espinaco V, Maurel J, Mármol M, Hörndler C, Ortego J, Alonso V, Escudero P, Ramírez G, Petry C, Lasalvia L, Bohmann K, Wirtz R, Mira A, Castells A.

Int J Cancer. 2013 Mar 1;132(5):1090-7. doi: 10.1002/ijc.27747. Epub 2012 Aug 12.

9.

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.

Maak M, Simon I, Nitsche U, Roepman P, Snel M, Glas AM, Schuster T, Keller G, Zeestraten E, Goossens I, Janssen KP, Friess H, Rosenberg R.

Ann Surg. 2013 Jun;257(6):1053-8. doi: 10.1097/SLA.0b013e31827c1180.

PMID:
23295318
10.

Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer.

Liu C, Eng C, Shen J, Lu Y, Takata Y, Mehdizadeh A, Chang GJ, Rodriguez-Bigas MA, Li Y, Chang P, Mao Y, Hassan MM, Wang F, Li D.

Oncotarget. 2016 Nov 15;7(46):76250-76260. doi: 10.18632/oncotarget.12841.

11.

Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M, Wang E.

JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413.

PMID:
26502222
12.

Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.

Jiang Y, Casey G, Lavery IC, Zhang Y, Talantov D, Martin-McGreevy M, Skacel M, Manilich E, Mazumder A, Atkins D, Delaney CP, Wang Y.

J Mol Diagn. 2008 Jul;10(4):346-54. doi: 10.2353/jmoldx.2008.080011. Epub 2008 Jun 13.

13.

Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse.

Kang WK, Lee JK, Oh ST, Lee SH, Jung CK.

BMC Gastroenterol. 2015 Jan 22;15:2. doi: 10.1186/s12876-015-0227-0. Review.

14.

Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.

Weissmann-Brenner A, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, Kundel Y, Morgenstern S, Halperin M, Niv Y, Brenner B.

Int J Oncol. 2012 Jun;40(6):2097-103. doi: 10.3892/ijo.2012.1403. Epub 2012 Mar 16.

PMID:
22426940
15.

Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer.

Hur K, Toiyama Y, Okugawa Y, Ide S, Imaoka H, Boland CR, Goel A.

Gut. 2017 Apr;66(4):654-665. doi: 10.1136/gutjnl-2014-308737. Epub 2015 Dec 23.

16.

MicroRNA classifier and nomogram for metastasis prediction in colon cancer.

Goossens-Beumer IJ, Derr RS, Buermans HP, Goeman JJ, Böhringer S, Morreau H, Nitsche U, Janssen KP, van de Velde CJ, Kuppen PJ.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):187-97. doi: 10.1158/1055-9965.EPI-14-0544-T. Epub 2014 Oct 14.

17.

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis.

Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin RA, Weiss LM, Wu H.

PLoS One. 2012;7(5):e35661. doi: 10.1371/journal.pone.0035661. Epub 2012 May 18.

18.

Down-regulation of let-7a-5p predicts lymph node metastasis and prognosis in colorectal cancer: Implications for chemotherapy.

Liu TP, Huang CC, Yeh KT, Ke TW, Wei PL, Yang JR, Cheng YW.

Surg Oncol. 2016 Dec;25(4):429-434. doi: 10.1016/j.suronc.2016.05.016. Epub 2016 May 27.

PMID:
27262492
19.

A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer.

Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP.

Sci Rep. 2018 Apr 18;8(1):6157. doi: 10.1038/s41598-018-24519-4.

20.

Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer.

Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M, Kiss I, Vyzula R, Slaby O.

Carcinogenesis. 2016 Oct;37(10):941-950. doi: 10.1093/carcin/bgw078. Epub 2016 Aug 1.

PMID:
27485599

Supplemental Content

Support Center